LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Varex Imaging Management to Participate in Upcoming Investor Conferences

February 02, 2025 | Last Trade: US$8.36 0.00 0.00

SALT LAKE CITY / Feb 02, 2025 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in the following upcoming investor conferences.

  • BTIG at Snowbird: The 12th Annual MedTech, Digital Health, LS&D Tools Conference in Salt Lake City, UT – Wednesday, February 12, 2025 (1x1 meetings only)
  • B. Riley Securities Precision Oncology & Radiopharma Conference – Friday, February 28, 2025 in New York, NY (1x1 meetings only)

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Viking Therapeutics

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page